Video

Dr. Philip on the Importance of Developing New Drugs for Pancreatic Cancer

Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the importance of developing new drugs for patients with pancreatic cancer.

Philip A. Philip, MD, PhD, FRCP, professor of Medicine, Wayne State University School of Medicine, clinical professor of Oncology at Barbara Ann Karmanos Cancer Institute, discusses the importance of developing new drugs for patients with pancreatic cancer.

Unlike other chemotherapy-resistant cancers that have seen developments in treatments, pancreatic cancer is lacking beneficial improvements of other treatments, states Philip.

According to Philip, it is expected that pancreatic cancer will be the second leading cause of cancer mortalities by 2020. Most of the patients with pancreatic cancer have metastatic disease, making the only way to control the natural history of the disease is by getting better systemic treatments.

Related Videos
Roxana S. Dronca, MD, discusses the FDA’s approval of subcutaneous nivolumab across solid tumor indications.
Craig Eckfeldt, MD
Whitney Goldsberry, MD
Jonathan Wesley Riess, MD, MS, an associate professor at the University of California (UC) Davis
Yair Lotan, MD, professor, urology, chief, urologic oncology, Jane and John Justin Distinguished Chair in Urology, UT Southwestern Harold C. Simmons Comprehensive Cancer Center; medical director, Urology Clinic, UT Southwestern and Parkland Health and Hospital System
Laura A. Huppert, MD
Polly Niravath, MD
Arvind N. Dasari, MD, MS
Charles E. Geyer, Jr., MD
Sattva S. Neelapu, MD